These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. Witkin JM; Lippa A; Smith JL; Jin X; Ping X; Biggerstaff A; Kivell BM; Knutson DE; Sharmin D; Pandey KP; Mian MY; Cook JM; Cerne R Pharmacol Biochem Behav; 2022 Feb; 213():173321. PubMed ID: 35041859 [TBL] [Abstract][Full Text] [Related]
9. The Positive Allosteric Modulator of Witkin JM; Li G; Golani LK; Xiong W; Smith JL; Ping X; Rashid F; Jahan R; Cerne R; Cook JM; Jin X J Pharmacol Exp Ther; 2020 Jan; 372(1):83-94. PubMed ID: 31694876 [TBL] [Abstract][Full Text] [Related]
10. GABAA receptor subtype-selective modulators. I. α2/α3-selective agonists as non-sedating anxiolytics. Atack JR Curr Top Med Chem; 2011; 11(9):1176-202. PubMed ID: 21050172 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA Poe MM; Methuku KR; Li G; Verma AR; Teske KA; Stafford DC; Arnold LA; Cramer JW; Jones TM; Cerne R; Krambis MJ; Witkin JM; Jambrina E; Rehman S; Ernst M; Cook JM; Schkeryantz JM J Med Chem; 2016 Dec; 59(23):10800-10806. PubMed ID: 27933953 [TBL] [Abstract][Full Text] [Related]
13. Both alpha2 and alpha3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Morris HV; Dawson GR; Reynolds DS; Atack JR; Stephens DN Eur J Neurosci; 2006 May; 23(9):2495-504. PubMed ID: 16706856 [TBL] [Abstract][Full Text] [Related]
14. Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. Fradley RL; Guscott MR; Bull S; Hallett DJ; Goodacre SC; Wafford KA; Garrett EM; Newman RJ; O'Meara GF; Whiting PJ; Rosahl TW; Dawson GR; Reynolds DS; Atack JR J Psychopharmacol; 2007 Jun; 21(4):384-91. PubMed ID: 17092983 [TBL] [Abstract][Full Text] [Related]
15. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Atack JR Expert Opin Investig Drugs; 2005 May; 14(5):601-18. PubMed ID: 15926867 [TBL] [Abstract][Full Text] [Related]
16. Effects of the α2/α3-subtype-selective GABAA receptor positive allosteric modulator KRM-II-81 on pain-depressed behavior in rats: comparison with ketorolac and diazepam. Moerke MJ; Li G; Golani LK; Cook J; Negus SS Behav Pharmacol; 2019 Aug; 30(5):452-461. PubMed ID: 30640180 [TBL] [Abstract][Full Text] [Related]
17. An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA Methuku KR; Li X; Cerne R; Gleason SD; Schkeryantz JM; Tiruveedhula VVNPB; Golani LK; Li G; Poe MM; Rahman MT; Cook JM; Fisher JL; Witkin JM Pharmacol Biochem Behav; 2018 Jul; 170():9-13. PubMed ID: 29715490 [TBL] [Abstract][Full Text] [Related]
18. GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics. Atack JR Curr Top Behav Neurosci; 2010; 2():331-60. PubMed ID: 21309116 [TBL] [Abstract][Full Text] [Related]
19. GABA A receptor subtype selectivity underlying selective anxiolytic effect of baicalin. Wang F; Xu Z; Ren L; Tsang SY; Xue H Neuropharmacology; 2008 Dec; 55(7):1231-7. PubMed ID: 18723037 [TBL] [Abstract][Full Text] [Related]
20. Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure. Fischer BD; Licata SC; Edwankar RV; Wang ZJ; Huang S; He X; Yu J; Zhou H; Johnson EM; Cook JM; Furtmüller R; Ramerstorfer J; Sieghart W; Roth BL; Majumder S; Rowlett JK Neuropharmacology; 2010 Dec; 59(7-8):612-8. PubMed ID: 20727364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]